Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)
23.79
+1.76 (7.99%)
At close: Sep 23, 2026
Jiangsu CoWin Biotech Revenue
Jiangsu CoWin Biotech had revenue of 54.02M CNY in the quarter ending June 30, 2026, with 22.46% growth. This brings the company's revenue in the last twelve months to 219.42M, up 50.45% year-over-year. In the year 2025, Jiangsu CoWin Biotech had annual revenue of 193.52M with 53.74% growth.
Revenue (ttm)
219.42M
Revenue Growth
+50.45%
P/S Ratio
11.92
Revenue / Employee
299.76K
Employees
732
Market Cap
2.62B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 193.52M | 67.64M | 53.74% |
| Dec 31, 2024 | 125.88M | -45.47M | -26.54% |
| Dec 31, 2023 | 171.34M | -350.26M | -67.15% |
| Dec 31, 2022 | 521.60M | 183.14M | 54.11% |
| Dec 31, 2021 | 338.46M | 105.25M | 45.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.15B |
| Shandong Sito Bio-technology | 1.12B |
| Guangdong VTR Bio-Tech | 814.07M |
| Guiyang Xintian Pharmaceutical | 723.26M |
| Jilin Jian Yisheng Pharmaceutical | 650.83M |
| Hubei Goto Biopharm Group | 650.05M |
| Suzhou Fushilai Pharmaceutical | 394.29M |
| Yantai Zhenghai Biotechnology | 336.07M |